Does an inability to eradicate normal stem cells preclude the cure of some cancers?
Presently, identified signal transduction pathways do not alter normal stem-cell survival. With prostate cancer as a model, the argument is advanced that an inability to eradicate normal androgen-dependent prostate stem-cells precludes successful treatment of transformed, androgen-independent and metastatic progeny. While applying this idea to cancers of non-essential organs or to endocrine cancers seems feasible, the inutility of this approach for most other malignancies appears likely, although not certain.